本文選題：扶正化瘀片 + 慢性肝炎肝硬化　； 參考：《遼寧中醫(yī)雜志》2017年09期

【摘要】：目的:探究扶正化瘀片聯(lián)合西藥治療慢性肝炎肝硬化的臨床效果。方法:將2014年6月—2017年6月期間的156例慢性肝炎肝硬化患者隨機分成兩組,對照組采用替卡韋片治療,觀察組采用扶正化瘀片聯(lián)合恩替卡韋治療,比較兩組患者血清血清天冬氨酸氨基轉(zhuǎn)移酶(AST)、丙氨酸氨基轉(zhuǎn)移酶(ALT)水平,腫瘤壞死因子-α(TNF-α)、白細胞介素-6(IL-6)、白細胞介素-8(IL-8)水平以及HBV-DNA載量。結(jié)果:治療后,觀察組患者血清血清AST、ALT水平,炎癥介質(zhì)TNF-α、IL-6和IL-8水平以及HBV-DNA載量均明顯的低于對照組,HBV-DNA轉(zhuǎn)陰率明顯高于對照組,比較差異具有顯著性(P0.05)。結(jié)論:扶正化瘀片聯(lián)合恩替卡韋降低了肝臟炎癥,提高了HBV-DNA轉(zhuǎn)陰率,有效的改善了肝功能。
[Abstract]:Objective: to explore the clinical effect of Fuzheng Huayu tablet combined with western medicine in the treatment of chronic hepatitis cirrhosis.Methods: 156 patients with chronic hepatitis cirrhosis from June 2014 to June 2017 were randomly divided into two groups: the control group was treated with tekavir tablet, the observation group was treated with Fuzheng Huayu tablet combined with entecavir.The serum levels of aspartate aminotransferase (AST), alanine aminotransferase (alt), tumor necrosis factor- 偽 (TNF- 偽), interleukin-6 (IL-6), interleukin-8 (IL-8) and HBV-DNA load were compared between the two groups.Results: after treatment, the levels of serum alt, TNF- 偽 IL-6, IL-8 and HBV-DNA load in the observation group were significantly lower than those in the control group, and the negative rate of HBV-DNA in the control group was significantly higher than that in the control group (P 0.05).Conclusion: Fuzheng Huayu tablet combined with entecavir can reduce liver inflammation, increase HBV-DNA negative rate and improve liver function effectively.
【作者單位】： 新疆石河子大學醫(yī)學院第一附屬醫(yī)院功能科;新疆石河子人民醫(yī)院消化內(nèi)科;新疆石河子大學醫(yī)學院第一附屬醫(yī)院中醫(yī)科;
【基金】：新疆維吾爾自治區(qū)自然科學基金(160030052)
【分類號】：R575

【相似文獻】

相關期刊論文 前1條

1 李從陽;;扶正化瘀解毒方加拉米夫定治療慢性乙型肝炎肝纖維化療效觀察[J];海南醫(yī)學;2007年10期

，

本文編號：1760982